Compare Stocks: HURA, ARVN, CAPR, and AUTL

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ARVN Arvinas	$7.79 -0.5%	$8.71	$6.97 ▼ $14.51	$549.08M	1.75	783,831 shs	1.22 million shs
AUTL Autolus Therapeutics	$1.91 -2.1%	$1.99	$1.18 ▼ $2.58	$540.31M	2.1	1.50 million shs	1.82 million shs
CAPR Capricor Therapeutics	$8.57 -1.2%	$8.81	$2.96 ▼ $40.37	$543.02M	0.72	4.10 million shs	2.40 million shs
HURA TuHURA Biosciences	$2.10 +2.4%	$2.14	$0.41 ▼ $3.43	$135.74M	-0.02	174,976 shs	194,487 shs

7 Stocks That Will Be Magnificent in 2026

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ARVN Arvinas	-0.51%	-6.26%	-18.85%	-3.05%	+0.78%
AUTL Autolus Therapeutics	-2.05%	-0.52%	-21.72%	+17.54%	+22.44%
CAPR Capricor Therapeutics	-1.15%	-9.02%	+3.38%	-67.59%	+38.45%
HURA TuHURA Biosciences	+2.44%	+0.48%	+2.94%	-5.62%	-18.29%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ARVN Arvinas	$7.79 -0.5%	$8.71	$6.97 ▼ $14.51	$549.08M	1.75	783,831 shs	1.22 million shs
AUTL Autolus Therapeutics	$1.91 -2.1%	$1.99	$1.18 ▼ $2.58	$540.31M	2.1	1.50 million shs	1.82 million shs
CAPR Capricor Therapeutics	$8.57 -1.2%	$8.81	$2.96 ▼ $40.37	$543.02M	0.72	4.10 million shs	2.40 million shs
HURA TuHURA Biosciences	$2.10 +2.4%	$2.14	$0.41 ▼ $3.43	$135.74M	-0.02	174,976 shs	194,487 shs

7 Stocks That Will Be Magnificent in 2026

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ARVN Arvinas	-0.51%	-6.26%	-18.85%	-3.05%	+0.78%
AUTL Autolus Therapeutics	-2.05%	-0.52%	-21.72%	+17.54%	+22.44%
CAPR Capricor Therapeutics	-1.15%	-9.02%	+3.38%	-67.59%	+38.45%
HURA TuHURA Biosciences	+2.44%	+0.48%	+2.94%	-5.62%	-18.29%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ARVN Arvinas	2.30	Hold	$14.55	86.72% Upside
AUTL Autolus Therapeutics	2.86	Moderate Buy	$10.00	423.56% Upside
CAPR Capricor Therapeutics	2.27	Hold	$30.25	252.98% Upside
HURA TuHURA Biosciences	2.67	Moderate Buy	$9.00	328.57% Upside

Current Analyst Ratings Breakdown

Latest HURA, ARVN, CAPR, and AUTL Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/17/2026	CAPR Capricor Therapeutics	Oppenheimer Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Outperform
9/14/2026	CAPR Capricor Therapeutics	B. Riley Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Neutral ➝ Buy	$5.00 ➝ $21.00
9/14/2026	CAPR Capricor Therapeutics	B. Riley Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Neutral ➝ Buy	$5.00 ➝ $21.00
9/11/2026	CAPR Capricor Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
9/3/2026	ARVN Arvinas	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
9/1/2026	CAPR Capricor Therapeutics	Piper Sandler Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Neutral ➝ Overweight
8/25/2026	CAPR Capricor Therapeutics	Oppenheimer Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Market Perform ➝ Outperform
8/18/2026	HURA TuHURA Biosciences	Citizens Jmp Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Market Outperform	$9.00
8/14/2026	CAPR Capricor Therapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Neutral ➝ Overweight
8/13/2026	ARVN Arvinas	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D)
8/13/2026	AUTL Autolus Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)

(Data available from 9/25/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ARVN Arvinas	$262.60M	1.91	N/A	N/A	$6.76 per share	1.15
AUTL Autolus Therapeutics	$75.39M	6.74	N/A	N/A	$0.67 per share	2.85
CAPR Capricor Therapeutics	$22.27M	22.37	N/A	N/A	$5.53 per share	1.55
HURA TuHURA Biosciences	N/A	N/A	N/A	N/A	$0.34 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ARVN Arvinas	-$80.80M	$0.10	77.91	N/A	N/A	2.94%	1.91%	1.29%	11/4/2026 (Estimated)
AUTL Autolus Therapeutics	-$287.53M	-$1.06	N/A	N/A	N/A	-238.66%	-178.66%	-49.34%	10/29/2026 (Estimated)
CAPR Capricor Therapeutics	-$105.04M	-$2.45	N/A	N/A	N/A	N/A	-56.60%	-43.97%	11/9/2026 (Estimated)
HURA TuHURA Biosciences	-$30.05M	-$0.54	N/A	N/A	N/A	N/A	-156.47%	-106.98%	11/13/2026 (Estimated)

Latest HURA, ARVN, CAPR, and AUTL Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2026	Q2 2026	HURA TuHURA Biosciences	-$0.1533	-$0.14	+$0.0133	-$0.14	N/A	N/A
8/13/2026	Q2 2026	CAPR Capricor Therapeutics	-$0.5889	-$0.70	-$0.1111	-$0.70	$2.08 million	N/A
8/11/2026	Q2 2026	AUTL Autolus Therapeutics	-$0.21	-$0.15	+$0.06	-$0.15	$38.56 million	$45.69 million
8/4/2026	Q2 2026	ARVN Arvinas	-$0.3741	$2.58	+$2.9541	$2.58	$60.71 million	$249.70 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ARVN Arvinas	N/A	N/A	N/A	N/A	N/A
AUTL Autolus Therapeutics	N/A	N/A	N/A	N/A	N/A
CAPR Capricor Therapeutics	N/A	N/A	N/A	N/A	N/A
HURA TuHURA Biosciences	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ARVN Arvinas	N/A	7.91	7.91
AUTL Autolus Therapeutics	1.04	4.89	4.40
CAPR Capricor Therapeutics	N/A	7.35	7.35
HURA TuHURA Biosciences	0.20	0.18	0.18

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ARVN Arvinas	95.19%
AUTL Autolus Therapeutics	72.83%
CAPR Capricor Therapeutics	21.68%
HURA TuHURA Biosciences	0.62%

Insider Ownership

Company	Insider Ownership
ARVN Arvinas	7.30%
AUTL Autolus Therapeutics	25.70%
CAPR Capricor Therapeutics	9.20%
HURA TuHURA Biosciences	6.06%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ARVN Arvinas	246	64.52 million	59.81 million	Optionable
AUTL Autolus Therapeutics	752	266.16 million	197.76 million	Optionable
CAPR Capricor Therapeutics	231	58.14 million	52.79 million	Optionable
HURA TuHURA Biosciences	22	63.73 million	59.87 million	N/A

HURA, ARVN, CAPR, and AUTL Headlines

Recent News About These Companies

TuHURA Biosciences Draws Additional Funds From Credit Facility

September 24 at 5:31 PM | tipranks.com

TuHURA Biosciences Expands Use of Revolving Credit Facility

September 17, 2026 | tipranks.com

TuHURA Biosciences, Inc. (NASDAQ:HURA) Receives Average Recommendation of "Moderate Buy" from Brokerages

September 17, 2026 | americanbankingnews.com

TuHURA Biosciences, Inc.: TuHURA Biosciences Receives FDA "Study May Proceed" Notice and IND Clearance for the Evaluation of its TBS-2025 VISTA-Inhibiting Antibody in ...

September 16, 2026 | finanznachrichten.de

TuHURA Biosciences Receives FDA IND Clearance For TBS-2025 In AML

September 14, 2026 | rttnews.com

TuHURA Biosciences Says FDA Clears Phase 1b Trial of TBS-2025 in Acute Myeloid Leukemia

September 14, 2026 | finance.yahoo.com

TuHURA Biosciences Receives FDA "Study May Proceed" Notice and IND Clearance for the Evaluation of its TBS-2025 VISTA-Inhibiting Antibody in Molecularly Defined Subsets of AML ...

September 14, 2026 | finance.yahoo.com

TuHURA Biosciences Receives FDA "Study May Proceed" Notice and IND Clearance for the Evaluation of its TBS-2025 VISTA-Inhibiting Antibody in Molecularly Defined Subsets of AML and Other Blood-Related Cancers

September 14, 2026 | prnewswire.com

TuHURA Biosciences, Inc. (NASDAQ:HURA) Receives Consensus Rating of "Moderate Buy" from Analysts

September 12, 2026 | marketbeat.com

TuHURA Biosciences to Present at the H.C. Wainwright 28th Annual Global Investment Conference

September 8, 2026 | prnewswire.com

BlackRock Inc. Purchases New Shares in TuHURA Biosciences, Inc. $HURA

September 7, 2026 | marketbeat.com

TuHURA Biosciences draws additional funds from credit facility

September 4, 2026 | tipranks.com

Equities Analysts Offer Predictions for HURA FY2026 Earnings

August 28, 2026 | marketbeat.com

HURA: Milestone Progression Over Next 12 Months

August 26, 2026 | finance.yahoo.com

TuHURA Biosciences Expands Use of Revolving Credit Facility

August 21, 2026 | tipranks.com

TuHURA Biosciences Reports Second Quarter 2026 Financial Results and Provides a Corporate Update

August 14, 2026 | prnewswire.com

TuHURA Biosciences Expands Use of Revolving Credit Facility

August 13, 2026 | tipranks.com

TuHURA Biosciences Expands Revolving Credit Facility Utilization

July 29, 2026 | tipranks.com

TuHURA Biosciences to Present at Canaccord Genuity's 46th Annual Growth Conference

July 22, 2026 | prnewswire.com

TuHURA Biosciences Expands Use of Revolving Credit Facility

July 7, 2026 | tipranks.com

TuHURA Biosciences, Inc.: TuHURA Biosciences Files Investigational New Drug Application for Evaluation of the TBS-2025 VISTA Inhibiting Antibody in Molecularly Defined Subsets ...

June 16, 2026 | finanznachrichten.de

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

HURA, ARVN, CAPR, and AUTL Company Descriptions

Arvinas NASDAQ:ARVN

$7.79 -0.04 (-0.51%)

Closing price 09/24/2026 04:00 PM Eastern

Extended Trading

$7.47 -0.32 (-4.08%)

As of 07:41 AM Eastern

Arvinas, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins. Its product pipeline includes Bavdegalutamide and ARV-766, investigational orally bioavailable PROTAC protein degraders for the treatment of men with metastatic castration-resistant prostate cancer, which are in Phase 1/2 clinical trials; and ARV-471, an orally bioavailable estrogen receptor degrading PROTAC targeted protein degrader for the treatment of patients with locally advanced or metastatic estrogen receptor+/human epidermal growth factor receptor 2-breast cancer, which is Phase 3 clinical trial. Arvinas, Inc. has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., Carrick Therapeutics Limited, and Bayer AG. The company was founded in 2013 and is based in New Haven, Connecticut.

Autolus Therapeutics NASDAQ:AUTL

$1.91 -0.04 (-2.05%)

Closing price 09/24/2026 04:00 PM Eastern

Extended Trading

$1.92 +0.02 (+0.79%)

As of 07:33 AM Eastern

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma. It focuses on developing AUTO5, a preclinical TRBC2 programmed T cell product candidate for the treatment of peripheral T-cell lymphoma. Autolus Therapeutics plc was incorporated in 2014 and is headquartered in London, the United Kingdom.

Capricor Therapeutics NASDAQ:CAPR

$8.57 -0.10 (-1.15%)

Closing price 09/24/2026 04:00 PM Eastern

Extended Trading

$8.65 +0.08 (+0.95%)

As of 07:31 AM Eastern

Capricor Therapeutics, Inc. (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor's lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy. Capricor has also established itself as one of the leading companies investigating the field of extracellular vesicles and is exploring the potential of CAP-2003, a cell-free, exosome-based candidate, to treat a variety of disorders.

TuHURA Biosciences NASDAQ:HURA

$2.10 +0.05 (+2.44%)

Closing price 09/24/2026 04:00 PM Eastern

Extended Trading

$2.11 +0.01 (+0.48%)

As of 04:07 AM Eastern

TuHURA Biosciences, Inc. (NASDAQ: HURA) is a Phase 3 registration-stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. TuHURA's lead innate immune response agonist candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. TuHURA is preparing to initiate a single randomized placebo-controlled Phase 3 registration trial of IFx-2.0 administered as an adjunctive therapy to Keytruda® (pembrolizumab) in first line treatment for advanced or metastatic Merkel Cell Carcinoma. In addition to its innate immune response agonist candidates, TuHURA is leveraging its Delta receptor technology to develop first-in-class bi-specific ADCs, and PDCs targeting Myeloid Derived Suppressor Cells to inhibit their immune suppressing effects on the tumor microenvironment to prevent T cell exhaustion and acquired resistance to checkpoint inhibitors and cellular therapies.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest HURA, ARVN, CAPR, and AUTL Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest HURA, ARVN, CAPR, and AUTL Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

HURA, ARVN, CAPR, and AUTL Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

HURA, ARVN, CAPR, and AUTL Company Descriptions

Arvinas NASDAQ:ARVN

Autolus Therapeutics NASDAQ:AUTL

Capricor Therapeutics NASDAQ:CAPR

TuHURA Biosciences NASDAQ:HURA

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest HURA, ARVN, CAPR, and AUTL Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest HURA, ARVN, CAPR, and AUTL Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

HURA, ARVN, CAPR, and AUTL Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

HURA, ARVN, CAPR, and AUTL Company Descriptions

Arvinas NASDAQ:ARVN

Autolus Therapeutics NASDAQ:AUTL

Capricor Therapeutics NASDAQ:CAPR

TuHURA Biosciences NASDAQ:HURA

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools